SH-105 Gets Accepted for FDA Review in Breast and Ovarian Ca

The FDA has announced that it had accepted the new drug application for SH-105 for the treatment of patients with breast and ovarian cancer.

Related Keywords

United States , Ireland , Irish , Shorla Pharma , Orlaith Ryan , Sharon Cunningham , Prescription Drug User Fee Act , Shorla Oncology , Sh 105 , Fda ,